COPD Clinical Trial Landscape

Why COPD trial monitoring is valuable in 2026

Chronic obstructive pulmonary disease (COPD) affects over 16 million diagnosed Americans and represents one of the largest unmet needs in respiratory medicine. Despite the commercial dominance of triple inhaled therapy (LAMA/LABA/ICS), the search for disease-modifying treatments, approaches that actually slow lung function decline rather than just manage symptoms, is driving an active and increasingly complex trial landscape.

Key competitive areas to monitor in the 2026 COPD pipeline:

• Type 2 inflammation biologics: dupilumab (IL-4Rα) approved for COPD in eosinophilic patients in 2024; multiple follow-on programs targeting IL-33, TSLP, and IL-13 entering COPD trials; competitive spillover from asthma biologics
• Non-type 2 / neutrophilic COPD: the majority of COPD patients are non-eosinophilic; IL-17, IL-8, CXCR2 programs targeting neutrophilic airway inflammation remain an active and unresolved competitive space
• Alpha-1 antitrypsin deficiency (AATD): a genetically defined COPD subtype; augmentation therapy is approved; gene therapy and AAT mimetic approaches entering trials (Takeda, Inhibrx, others)
• Lung tissue repair / regeneration: PDE4B inhibitors, senolytic agents, and matrix metalloproteinase programs targeting emphysema reversal
• COPD exacerbation prevention: anti-infective approaches, RSV vaccines, and novel anti-inflammatory programs targeting the exacerbation cascade
• Lung microbiome interventions: early phase programs examining microbiome modulation for COPD stability

What we monitor for COPD

Our daily ClinicalTrials.gov pipeline can be configured for precise COPD trial tracking:

• Condition keywords: "COPD", "chronic obstructive pulmonary disease", "emphysema", "chronic bronchitis", "alpha-1 antitrypsin deficiency", "AATD"
• Mechanism keywords: "IL-33 COPD", "TSLP COPD", "PDE4 COPD", "CXCR2", "senolytic COPD", "lung regeneration", track any specific mechanism
• Phase filter: Focus on Phase 2/3 for near-term commercial threats, or include Phase 1 for early competitive intelligence
• Sponsor filter: Industry-sponsored only (competitive commercial landscape) or all including academic
• Population subtype: Keywords like "eosinophilic", "non-eosinophilic", "frequent exacerbator", "GOLD 2-4" for subgroup-specific monitoring

The dupilumab approval and its competitive ripple effects

FDA approval of dupilumab for COPD in eosinophilic patients in 2024 marked the first new mechanism approved for COPD in decades and opened the floodgates for type 2 biologic trials in the condition. The competitive landscape that has emerged:

• Astegolimab (IL-33, Genentech/Roche): completed Phase 3 in COPD; results define the competitive ceiling for IL-33 approaches
• Itepekimab (IL-33, Sanofi/Regeneron): Phase 3 AERIFY program ongoing; direct IL-33 vs. IL-4Rα competitive question
• Tezepelumab (TSLP, AZ/Amgen): approved in asthma; COPD program underway
• Multiple next-generation type 2 biologics entering Phase 2 COPD trials following dupilumab's success

BD teams and investors tracking the COPD biologic space need visibility into new trial registrations the moment they appear on ClinicalTrials.gov.

Active Phase 3 COPD Pipeline: 2026

The following programs represent the major industry-sponsored Phase 3 trials currently active or recruiting in COPD as tracked in our database:

The biologic race in eosinophilic COPD: IL-33 vs. TSLP vs. dual-target

Dupilumab's 2024 approval in eosinophilic COPD validated the type 2 inflammation hypothesis in COPD, but it also opened the question of which upstream cytokine is the better target. The 2025–2026 Phase 3 landscape now pits four approaches against each other:

• IL-4Rα blockade (dupilumab): the approved benchmark, blocking both IL-4 and IL-13 signaling; ~34% reduction in exacerbation rate in BOREAS/NOTUS trials
• Anti-IL-33 (tozorakimab, astegolimab): IL-33 is upstream of IL-4/13 and also drives non-type-2 inflammation; tozorakimab's AERIFY program showed exacerbation reduction in non-eosinophilic COPD, potentially expanding beyond the eosinophilic subgroup
• Anti-TSLP (tezepelumab): DESTINATION study in mod-to-very-severe COPD; TSLP sits at the top of the type 2 cascade; established precedent from asthma where tezepelumab outperformed eosinophil-dependent biologics in mixed populations
• IL-33/TSLP bispecific (lunsekimig): Sanofi's Phase 3 program blocks both upstream alarmins simultaneously; the hypothesis is additive benefit, but bispecific complexity is a manufacturing and regulatory risk

The competitive question for BD analysts: does blocking one alarmin (IL-33 or TSLP) provide the same benefit as dual blockade, or does each pathway contribute independently? Phase 3 readouts from tezepelumab and lunsekimig (expected 2026–2027) will answer that question directly.

Ensifentrine: the first new non-biologic COPD mechanism in a decade

FDA approval of ensifentrine (Ohtuvayre, Verona Pharma) in July 2024 as a nebulized dual PDE3/PDE4 inhibitor was the first new inhaled mechanism approved for COPD since aclidinium in 2012. Ensifentrine provides both bronchodilation (PDE3 inhibition) and anti-inflammatory effects (PDE4 inhibition) in a single molecule. The ENHANCE-1 and ENHANCE-2 Phase 3 trials demonstrated significant improvement in FEV1 and quality of life versus placebo. Post-approval investigation of ensifentrine combinations with LAMA/LABA is underway, competitive intelligence on those Phase 2/3 combination trials is now actionable for device and inhaler companies tracking the space.

Who uses COPD trial monitoring

• Respiratory/pulmonary BD teams at pharma and biotech: tracking competitor programs across COPD subtypes and mechanisms
• Respiratory disease investors: monitoring pipeline milestones and competitive positioning
• Pulmonology-focused CROs: identifying enrollment competition for active COPD studies
• COPD patient advocacy organizations (COPD Foundation, Alpha-1 Foundation): staying current on trial availability
• Pulmonologists and academic researchers: monitoring commercial pipeline for collaboration or IIT opportunities

Frequently asked questions